Retrospective Study
Copyright ©The Author(s) 2015.
World J Transplant. Sep 24, 2015; 5(3): 102-109
Published online Sep 24, 2015. doi: 10.5500/wjt.v5.i3.102
Figure 3
Figure 3 Adjusted patient survival (A-C) in peak-panel reactive antibody classes 0%-30%, 31%-60% and > 60% respectively. Note the inferior patient survival associated with steroid maintenance in peak-PRA groups 0%-30% and 31%-60%. PRA: Panel reactive antibody.